American Heart Journal
Volume 148, Issue 6 , Pages 1003-1006, December 2004

GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention

  • Jose E. Exaire, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Sorin J. Brener, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Stephen G. Ellis, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Jay S. Yadav, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Deepak L. Bhatt, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • Corresponding Author InformationReprint requests: Deepak L. Bhatt, MD, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, F25, Cleveland, OH 44195, USA.

Received 15 March 2004; accepted 23 June 2004.

Abstract 

Background

Use of emboli protection devices (EPD) during saphenous vein graft percutaneous coronary intervention (SVG-PCI) has been proven to reduce major adverse cardiac events (MACE). However, the impact of EPD on the microcirculation using Thrombolysis in Myocardial Infarction myocardial perfusion grade (TMP) has not been fully characterized. We sought to analyze TMP after SVG-PCI with and without EPD and determine its impact on inhospital MACE.

Methods

From August 2001 to December 2002, 305 patients had SVG-PCI suitable for EPD; 210 (69%) had an angiogram appropriate for TMP evaluation. Of those, 46 (22%) had an EPD (GuardWire, Medtronic, Minneapolis, Minn) deployed during the coronary intervention. Both groups were similar with regard to most demographic and clinical features.

Results

A TMP score of 2.5 or 3 was obtained in 98% of the EPD group versus 85% of the unprotected SVG-PCI (P = .01). There was a trend towards reduction in MACE when using EPD (15% vs 27%, respectively, P = .07). Peak postprocedural creatine kinase-MB was somewhat lower in the EPD group (6.03 ± 7.8 ng/mL vs 14.87 ± 42 ng/mL, P = .17) Patients with a TMP grade of 2.5 or 3 had a statistically significant reduction in MACE (OR 0.36, 95% CI 0.14–0.87, P = .02).

Conclusions

Compared with SVG-PCI without emboli protection, EPD significantly improved TMP and trended towards a reduction in MACE.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-8703(04)00410-7

doi:10.1016/j.ahj.2004.06.015

American Heart Journal
Volume 148, Issue 6 , Pages 1003-1006, December 2004

Article Tools